RHÖN-KLINIKUM AG

  • WKN: 704230
  • ISIN: DE0007042301
  • Land: Deutschland

Nachricht vom 21.09.2012 | 14:45

RHÖN-KLINIKUM AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


RHÖN-KLINIKUM AG 

21.09.2012 14:45

Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------


Notification according to section 26 para. 1 WpHG 

UBS AG, Zürich, Switzerland, notified us on 20 September 2012 pursuant to
section 25 WpHG and section 25a WpHG of the following:

1) UBS AG, Zürich, Switzerland, notified us pursuant to section 25 WpHG of
the following:

On 14 September 2012, UBS AG exceeded the threshold of 5% of the voting
rights of RHÖN-KLINIKUM AG, Salzburger Leite 1, 97616 Bad Neustadt a. d.
Saale, Germany. On that date, UBS AG held 5.15% of the voting rights in
RHÖN-KLINIKUM AG (equals 7,125,009 voting rights).

From these voting rights a proportion of 0.36% (equals 498,779 voting
rights) is based on voting rights pursuant to sections 21, 22 WpHG and a
proportion of 4.79% (equals 6,626,230 voting rights) is based on
(financial/other) instruments pursuant to section 25 WpHG. From the voting
rights based on instruments pursuant to section 25 WpHG a proportion of
0.00% (equals 0 voting rights) is held indirectly. The exercise period of
the instruments pursuant to section 25 WpHG is at any time with the
expiration date 21 September 2012.

2) UBS AG, Zürich, Switzerland, notified us pursuant to section 25a WpHG of
the following:

On 14 September 2012, UBS AG exceeded the threshold of 5% of the voting
rights of RHÖN-KLINIKUM AG, Salzburger Leite 1, 97616 Bad Neustadt a. d.
Saale, Germany. On that date, UBS AG held 5.16% of the voting rights in
RHÖN-KLINIKUM AG (equals 7,126,067 voting rights).

From these voting rights a proportion of 0.001% (equals 1,058 voting
rights) is based on (financial/other) instruments pursuant to section 25a
WpHG. From these voting rights based on instruments pursuant to section 25a
WpHG a proportion of 0.00% (equals 0 voting rights) is held indirectly.

In addition, a proportion of 4.79% (equals 6,626,230 voting rights) is
based on (financial/other) instruments pursuant to section 25 WpHG. From
these voting rights based on instruments pursuant to section 25 WpHG a
proportion of 0.00% (equals 0 voting rights) is held indirectly.

In addition, a proportion of 0.36% (equals 498,779 voting rights) is based
on voting rights pursuant to sections 21, 22 WpHG.

The (financial/other) instruments pursuant to section 25a WpHG are
described as follows:
- 'Equity Swaps' (expiration date 4 February 2015).

3) UBS AG, Zürich, Switzerland, notified us pursuant to section 25 WpHG of
the following:

On 17 September 2012, UBS AG fell below the threshold of 5% of the voting
rights of RHÖN-KLINIKUM AG, Salzburger Leite 1, 97616 Bad Neustadt a. d.
Saale, Germany. On that date, UBS AG held 4.25% of the voting rights in
RHÖN-KLINIKUM AG (equals 5,874,635 voting rights).

From these voting rights a proportion of 0.33% (equals 457,330 voting
rights) is based on voting rights pursuant to sections 21, 22 WpHG and a
proportion of 3.92% (equals 5,417,305 voting rights) is based on
(financial/other) instruments pursuant to section 25 WpHG. From the voting
rights based on instruments pursuant to section 25 WpHG a proportion of
0.00% (equals 0 voting rights) is held indirectly. The exercise period of
the instruments pursuant to section 25 WpHG is at any time with the
expiration date 21 September 2012.

4) UBS AG, Zürich, Switzerland, notified us pursuant to section 25a WpHG of
the following:

On 17 September 2012, UBS AG fell below the threshold of 5% of the voting
rights of RHÖN-KLINIKUM AG, Salzburger Leite 1, 97616 Bad Neustadt a. d.
Saale, Germany. On that date, UBS AG held 4.25% of the voting rights in
RHÖN-KLINIKUM AG (equals 5,875,693 voting rights).

From these voting rights a proportion of 0.001% (equals 1,058 voting
rights) is based on (financial/other) instruments pursuant to section 25a
WpHG. From these voting rights based on instruments pursuant to section 25a
WpHG a proportion of 0.00% (equals 0 voting rights) is held indirectly.

In addition, a proportion of 3.92% (equals 5,417,305 voting rights) is
based on (financial/other) instruments pursuant to section 25 WpHG. From
these voting rights based on instruments pursuant to section 25 WpHG a
proportion of 0.00% (equals 0 voting rights) is held indirectly.

In addition, a proportion of 0.33% (equals 457,330 voting rights) is based
on voting rights pursuant to sections 21, 22 WpHG.

The (financial/other) instruments pursuant to section 25a WpHG are
described as follows:
- 'Equity Swaps' (expiration date 4 February 2015).

Bad Neustadt a.d. Saale, 21 September 2012

The Board of Management

___________________________________________________________________

Dr. Kai G. Klinger
Head of Investor Relations
RHÖN-KLINIKUM AG
Schlossplatz 1
97616 Bad Neustadt a. d. Saale
Phone: +49 9771 65 - 1318
Fax: +49 9771 99 - 1736



21.09.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      RHÖN-KLINIKUM AG
              Schlossplatz 1
              97616 Bad Neustadt a.d.Saale
              Germany
Internet:     www.rhoen-klinikum-ag.com
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------

Anleihe im Fokus

Die DF-Anleihe 7,875%

Mit der DF Forfait AG vom wachsenden Welthandel profitieren

- Zeichnungsfrist: 21.05. bis 24.05.2013
- Laufzeit: 7 Jahre
- Kupon: 7,875% p.a.
- Volumen: bis zu 30 Mio. Euro
- ISIN: DE000A1R1CC4

Anleihe im Fokus

7,75% p.a. - Rendite aus Familienhand

– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs

GBC-Fokusbox

HELMA Eigenheimbau AG: Kaufen

Die HELMA Eigenheimbau AG präsentierte für das Geschäftsjahr 2012 Rekordwerte. Auf Basis unseres DCF-Modells haben wir einen fairen Wert je Aktie von 22,75 € ermittelt. Ausgehend vom erwarteten 2013er-EPS von 1,64 € entspricht dies einem KGV von 8,4. Das Kurspotenzial beläuft sich auf nahezu 65%.

News im Fokus

Fresenius Medical Care AG & Co. KGaA: Bekanntmachung nach Art. 4 Abs. 2 der Verordnung (EG) Nr. 2273/2003

17. Mai 2013, 17:35

Aktueller Webcast

Allianz SE

Analysts' conference call on 1Q 2013

15. Mai 2013

Aktuelle Research-Studie

Original-Research: Plan Optik AG (von GBC AG): Kaufen Plan Optik AG

17. Mai 2013